Geron (GON) Q2 2026 Earnings Report

Overall the call conveyed positive commercial momentum and strengthening scientific evidence for RYTELO and the myelofibrosis program, supported by revenue growth (Q2 $57.5M, +17% YoY, +11% QoQ), expanding accounts and encouraging real-world data. The company also highlighted operational discipline (H1 operating expense down ~4% vs H1 revenue +24%) and a solid cash position ($327M). Counterbalancing these positives are rising gross-to-net deductions (20.7% in Q2 vs 15.3% prior year), a modest quarter-over-quarter cash decline, ongoing investment-driven spending, uncertainty around interim analysis modifications for IMpactMF, and unresolved EU pricing/MFN complexities that could affect ex-U.S. expansion. On balance the favorable revenue, evidence generation, and execution momentum outweigh the manageable risks and uncertainties.

The company reiterated 2026 financial guidance and operational targets: Q2 net revenue was $57.5M (up 17% YoY and 11% QoQ; Q2 2025 was $49.0M) and H1 net revenue grew ~24% YoY, and Geron now expects to land at the mid‑ to high‑end of its full‑year RYTELO net product revenue guidance of $220M–$240M; total operating expense guidance remains $230M–$240M. Q2 gross‑to‑net was 20.7% (vs 15.3% in Q2 2025) and management expects gross‑to‑net in the low‑ to mid‑20s for the remainder of 2026, with inventory managed at 2–4 weeks. Q2 operating highlights included R&D of $22.0M (vs $21.7M), SG&A of $38.9M (vs $38.6M), total operating expenses excluding COGS of $60.7M (vs $60.3M), a 4% decrease in total operating expenses in H1 vs prior year, and cash, cash equivalents and marketable securities of ~$327M at June 30 (down from $341M at March 31). Commercial metrics and pipeline timing noted as guidance drivers: 5% demand growth in Q2 vs Q1, an 8% increase in prescribing accounts to ~1,575 since launch, 34% first‑ and second‑line patient starts on a rolling 12‑month basis, an estimated ~8,000 U.S. eligible second‑line lower‑risk MDS patients, and IMpactMF base‑case timing unchanged with a final overall survival analysis targeted in H2 2028 while the interim event threshold is being evaluated.